An interventional study of Axoguard HA+ Nerve Protector and Parotidectomy in Parotidectomy, Patient-reported Outcomes, Parotid Cancer and Parotid Gland Tumor, sponsored by Milton S. Hershey Medical Center. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Milton S. Hershey Medical Center · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the efficacy of AxoGuard HA+ (hyaluronic acid nerve protector) in preventing Frey syndrome following parotidectomy. A parotidectomy is a surgical procedure to remove all or part of the parotid gland, the largest salivary gland located near the ear and jaw. The specific aims are to determine whether placement of AxoGuard HA+ during parotidectomy can significantly reduce both clinical and subclinical incidence of Frey syndrome compared to standard surgical technique alone.
28 studies on the registry are indexed under Parotid Neoplasms; 8 are open to participants now.
This study's planned enrollment of 20 is below the median of 50 across 19 interventional studies indexed under Parotid Neoplasms.
Browse Parotid Neoplasms studies →Milton S. Hershey Medical Center is the lead sponsor of 493 studies on the registry; 60 are open to participants now.
Of its 58 completed or terminated interventional studies of FDA-regulated products, 46 (79%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Parotidectomy - Standard of Care
Procedure: Parotidectomy
Parotidectomy - With use of nerve protector
Device: Axoguard HA+ Nerve Protector
AxoGuard HA+ nerve protector is an FDA-approved device available for clinical use, but its specific efficacy in preventing Frey syndrome following parotidectomy has not been systematically evaluated in controlled trials.
A parotidectomy is a surgical procedure to remove all or part of the parotid gland, the largest salivary gland located near the ear and jaw.
Number of subjects with positive Starch-Iodine test
Time frame: 3 months post-op
Number of subjects with positive Starch-Iodine test
Time frame: 12 months post-op
Number of subjects experiencing a reduction in clinically reported symptoms of Frey Syndrome
Facial sweating, flushing, warmth/burning sensation, tingling/prickling, itching, and symptoms associated with chewing.
Time frame: 1 month pot-op
Number of subjects experiencing a reduction in clinically reported symptoms of Frey Syndrome
Facial sweating, flushing, warmth/burning sensation, tingling/prickling, itching, and symptoms associated with chewing.
Time frame: 3 months pot-op
Number of subjects experiencing a reduction in clinically reported symptoms of Frey Syndrome
Facial sweating, flushing, warmth/burning sensation, tingling/prickling, itching, and symptoms associated with chewing.
Time frame: 12 months pot-op
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Jan 2029, 24 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Milton S. Hershey Medical Center →